000			02708 am a22003013u 4500
042			_adc
100	1	0	_aKenny, Louise C. _eauthor _92659
700	1	0	_aBroadhurst, David I. _eauthor _92660
700	1	0	_aDunn, Warwick _eauthor _92661
700	1	0	_aBrown, Marie _eauthor _92662
700	1	0	_aNorth, Robyn A. _eauthor _92663
700	1	0	_aMcCowan, Lesley _eauthor _92664
700	1	0	_aRoberts, Claire _eauthor _92665
700	1	0	_aCooper, Garth J.S. _eauthor _92666
700	1	0	_aKell, Douglas B. _eauthor _92667
700	1	0	_aBaker, Philip N. _eauthor _92668
245	0	0	_aRobust Early Pregnancy Prediction of Later Preeclampsia Using Metabolomic Biomarkers
260			_c2010-10-01.
500			_a/pmc/articles/PMC7614124/
500			_a/pubmed/20837882
520			_aPreeclampsia is a pregnancy-specific syndrome that causes substantial maternal and fetal morbidity and mortality. The etiology is incompletely understood, and there is no clinically useful screening test. Current metabolomic technologies have allowed the establishment of metabolic signatures of preeclampsia in early pregnancy. Here, a 2-phase discovery/validation metabolic profiling study was performed. In the discovery phase, a nested case-control study was designed, using samples obtained at 15±1 weeks' gestation from 60 women who subsequently developed preeclampsia and 60 controls taking part in the prospective Screening for Pregnancy Endpoints cohort study. Controls were proportionally population matched for age, ethnicity, and body mass index at booking. Plasma samples were analyzed using ultra performance liquid chromatography-mass spectrometry. A multivariate predictive model combining 14 metabolites gave an odds ratio for developing preeclampsia of 36 (95% CI: 12 to 108), with an area under the receiver operator characteristic curve of 0.94. These findings were then validated using an independent case-control study on plasma obtained at 15±1 weeks from 39 women who subsequently developed preeclampsia and 40 similarly matched controls from a participating center in a different country. The same 14 metabolites produced an odds ratio of 23 (95% CI: 7 to 73) with an area under receiver operator characteristic curve of 0.92. The finding of a consistent discriminatory metabolite signature in early pregnancy plasma preceding the onset of preeclampsia offers insight into disease pathogenesis and offers the tantalizing promise of a robust presymptomatic screening test. (Hypertension. 2010;56:741-749.)
540			_a
546			_aen
690			_aArticle
655	7		_aText _2local
786	0		_nHypertension
856	4	1	_uhttp://dx.doi.org/10.1161/HYPERTENSIONAHA.110.157297 _zConnect to this object online.
999			_c2208 _d2208